TMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TransMedics Group Inc (TMDX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, positive growth outlook, and expansion plans outweigh the minor insider selling and neutral hedge fund sentiment. The current pre-market price of $110.45 is within a reasonable range, and the stock has long-term growth potential in the organ transplant market.
The MACD is positive and contracting, suggesting bullish momentum. RSI is neutral at 44.632, and moving averages are converging, indicating a consolidation phase. Key support is at 99.609, and resistance levels are at 116.134 and 121.239. The stock is trading close to its pivot level of 107.872, showing potential for upward movement.
Strong financial performance in Q4 2025 with revenue up 32.18% YoY and net income up 1436.87% YoY.
Expansion plans for the OCS kidney system and European markets.
Analysts maintain positive ratings, with price targets ranging from $118 to $175, indicating potential upside.
Insider selling has increased by 186.38% in the last month.
Evercore ISI recently lowered its price target to $118 from $170, reflecting some cautious sentiment.
In Q4 2025, revenue increased to $160.76M (up 32.18% YoY), net income surged to $105.38M (up 1436.87% YoY), and EPS rose to 2.58 (up 1257.89% YoY). However, gross margin slightly declined to 58.11% (-1.86% YoY).
Analysts generally maintain positive ratings, with multiple firms raising price targets following strong Q4 results. Recent price targets range from $118 to $175, with most firms highlighting growth potential in the organ transplant market and European expansion plans.
